Chemomab Therapeutics Stock Forecast - Simple Moving Average
| CMMB Stock | USD 1.71 0.01 0.58% |
The Simple Moving Average forecasted value of Chemomab Therapeutics Ltd on the next trading day is expected to be 1.71 with a mean absolute deviation of 0.09 and the sum of the absolute errors of 5.06. Chemomab Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Chemomab Therapeutics stock prices and determine the direction of Chemomab Therapeutics Ltd's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Chemomab Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time the rsi of Chemomab Therapeutics' share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (0.04) | EPS Estimate Current Year (0.08) | EPS Estimate Next Year (0.20) | Wall Street Target Price 17.5 |
Using Chemomab Therapeutics hype-based prediction, you can estimate the value of Chemomab Therapeutics Ltd from the perspective of Chemomab Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Moving Average forecasted value of Chemomab Therapeutics Ltd on the next trading day is expected to be 1.71 with a mean absolute deviation of 0.09 and the sum of the absolute errors of 5.06. Chemomab Therapeutics after-hype prediction price | USD 1.71 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Chemomab Therapeutics to cross-verify your projections. Chemomab Therapeutics Additional Predictive Modules
Most predictive techniques to examine Chemomab price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Chemomab using various technical indicators. When you analyze Chemomab charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Chemomab Therapeutics Simple Moving Average Price Forecast For the 25th of January
Given 90 days horizon, the Simple Moving Average forecasted value of Chemomab Therapeutics Ltd on the next trading day is expected to be 1.71 with a mean absolute deviation of 0.09, mean absolute percentage error of 0.01, and the sum of the absolute errors of 5.06.Please note that although there have been many attempts to predict Chemomab Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Chemomab Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Chemomab Therapeutics Stock Forecast Pattern
| Backtest Chemomab Therapeutics | Chemomab Therapeutics Price Prediction | Buy or Sell Advice |
Chemomab Therapeutics Forecasted Value
In the context of forecasting Chemomab Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Chemomab Therapeutics' downside and upside margins for the forecasting period are 0.02 and 5.91, respectively. We have considered Chemomab Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Chemomab Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Chemomab Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 110.0525 |
| Bias | Arithmetic mean of the errors | 0.0354 |
| MAD | Mean absolute deviation | 0.0858 |
| MAPE | Mean absolute percentage error | 0.039 |
| SAE | Sum of the absolute errors | 5.06 |
Predictive Modules for Chemomab Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Chemomab Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Chemomab Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Chemomab Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Chemomab Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Chemomab Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Chemomab Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Chemomab Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Chemomab Therapeutics' historical news coverage. Chemomab Therapeutics' after-hype downside and upside margins for the prediction period are 0.09 and 5.91, respectively. We have considered Chemomab Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Chemomab Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Chemomab Therapeutics is based on 3 months time horizon.
Chemomab Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Chemomab Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Chemomab Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Chemomab Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.86 | 4.20 | 0.01 | 0.05 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.71 | 1.71 | 0.00 |
|
Chemomab Therapeutics Hype Timeline
Chemomab Therapeutics is currently traded for 1.71. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.05. Chemomab is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is expected to be very small, whereas the daily expected return is currently at -0.86%. %. The volatility of related hype on Chemomab Therapeutics is about 7792.21%, with the expected price after the next announcement by competition of 1.66. About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.92. Some equities with similar Price to Book (P/B) outperform the market in the long run. Chemomab Therapeutics recorded a loss per share of 1.44. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 26th of August 2025. Given the investment horizon of 90 days the next expected press release will be in about 9 days. Check out Historical Fundamental Analysis of Chemomab Therapeutics to cross-verify your projections.Chemomab Therapeutics Related Hype Analysis
Having access to credible news sources related to Chemomab Therapeutics' direct competition is more important than ever and may enhance your ability to predict Chemomab Therapeutics' future price movements. Getting to know how Chemomab Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Chemomab Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| KZIA | Kazia Therapeutics Ltd | 2.03 | 8 per month | 9.73 | 0.05 | 14.69 | (18.36) | 78.79 | |
| OCEA | Ocean Biomedical | (0.07) | 22 per month | 29.26 | 0.20 | 160.00 | (60.00) | 473.33 | |
| TOVX | Theriva Biologics | (0.02) | 10 per month | 0.00 | (0.07) | 10.53 | (10.00) | 35.76 | |
| ELAB | Elevai Labs Common | (2.64) | 5 per month | 0.00 | (0.42) | 5.71 | (14.29) | 38.62 | |
| CANF | Can Fite Biopharma | 0.02 | 3 per month | 0.00 | (0.16) | 10.40 | (8.59) | 38.42 | |
| BIVI | Biovie Inc | 0.01 | 8 per month | 0.00 | (0.18) | 6.62 | (7.30) | 19.38 | |
| XRTX | XORTX Therapeutics | (0.01) | 10 per month | 0.00 | (0.1) | 7.14 | (6.45) | 20.83 | |
| INM | InMed Pharmaceuticals | 0.02 | 15 per month | 0.00 | (0.16) | 7.48 | (9.30) | 30.84 | |
| CERO | CERo Therapeutics Holdings | 0.02 | 6 per month | 0.00 | (0.11) | 20.00 | (17.65) | 94.69 | |
| GLMD | Galmed Pharmaceuticals | 0.11 | 7 per month | 0.00 | (0.15) | 8.04 | (9.20) | 21.39 |
Other Forecasting Options for Chemomab Therapeutics
For every potential investor in Chemomab, whether a beginner or expert, Chemomab Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Chemomab Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Chemomab. Basic forecasting techniques help filter out the noise by identifying Chemomab Therapeutics' price trends.Chemomab Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chemomab Therapeutics stock to make a market-neutral strategy. Peer analysis of Chemomab Therapeutics could also be used in its relative valuation, which is a method of valuing Chemomab Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Chemomab Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Chemomab Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Chemomab Therapeutics shares will generate the highest return on investment. By undertsting and applying Chemomab Therapeutics stock market strength indicators, traders can identify Chemomab Therapeutics Ltd entry and exit signals to maximize returns.
Chemomab Therapeutics Risk Indicators
The analysis of Chemomab Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Chemomab Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting chemomab stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.52 | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.66 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Chemomab Therapeutics
The number of cover stories for Chemomab Therapeutics depends on current market conditions and Chemomab Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Chemomab Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Chemomab Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Chemomab Therapeutics Short Properties
Chemomab Therapeutics' future price predictability will typically decrease when Chemomab Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Chemomab Therapeutics Ltd often depends not only on the future outlook of the potential Chemomab Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Chemomab Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.5 M | |
| Cash And Short Term Investments | 14.3 M |
Check out Historical Fundamental Analysis of Chemomab Therapeutics to cross-verify your projections. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.